Revision as of 11:25, 13 May 2024

Back to Top

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main MCL page for current regimens.

9 regimens on this page 10 variants on this page

First-line therapy

CHOP

CHOP: Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Prednisone

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Nickenig et al. 2006 (GLSG '96)	1996-1998	Phase 3 (C)	MCP	Might have superior ORR
Lenz et al. 2005	2000-2002	Phase 3 (C)	R-CHOP	Inferior ORR

Chemotherapy

Cyclophosphamide (Cytoxan) 750 mg/m² IV once on day 1
Doxorubicin (Adriamycin) 50 mg/m² IV once on day 1
Vincristine (Oncovin) 1.4 mg/m² (maximum dose of 2 mg) IV once on day 1

Glucocorticoid therapy

Prednisone (Sterapred) 100 mg/m² PO once per day on days 1 to 5

21-day cycle for 6 to 8 cycles

References

Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M, Hiddemann W; German Low Grade Lymphoma Study Group. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005 Mar 20;23(9):1984-92. Epub 2005 Jan 24. link to original article PubMed
GLSG '96: Nickenig C, Dreyling M, Hoster E, Pfreundschuh M, Trumper L, Reiser M, Wandt H, Lengfelder E, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer. 2006 Sep 1;107(5):1014-22. link to original article contains dosing details in manuscript PubMed

Cyclophosphamide & Fludarabine (FC)

FC: Fludarabine, Cyclophosphamide

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Rule et al. 2015 (CRUK-UCL-MCLIII)	2002-2010	Phase 3 (C)	FCR	Inferior OS

Chemotherapy

Fludarabine (Fludara) by the following criteria:
- Standard patients: 40 mg/m² PO once per day on days 1 to 3
- Patients intolerant of the oral route: 25 mg/m² IV once per day on days 1 to 3
Cyclophosphamide (Cytoxan) by the following criteria:
- Standard patients: 250 mg/m² PO once per day on days 1 to 3
- Patients intolerant of the oral route: 250 mg/m² IV once per day on days 1 to 3

Supportive therapy

PJP prophylaxis was mandatory

28-day cycle for up to 8 cycles

References

CRUK-UCL-MCLIII: Rule S, Smith P, Johnson PW, Bolam S, Follows G, Gambell J, Hillmen P, Jack A, Johnson S, Kirkwood AA, Kruger A, Pocock C, Seymour JF, Toncheva M, Walewski J, Linch D. The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. Haematologica. 2016 Feb;101(2):235-40. Epub 2015 Nov 26. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00641095

FCR

FCR: Fludarabine, Cyclophosphamide, Rituximab
R-FC: Rituximab, Fludarabine, Cyclophosphamide

Regimen variant #1, 30/250/375

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Kluin-Nelemans et al. 2012 (MCLelderly)	2004-2010	Phase 3 (E-switch-ic)	R-CHOP	Inferior OS (secondary endpoint)

Chemotherapy

Fludarabine (Fludara) 30 mg/m² IV once per day on days 1 to 3
Cyclophosphamide (Cytoxan) 250 mg/m² IV once per day on days 1 to 3

Targeted therapy

Rituximab (Rituxan) 375 mg/m² (maximum dose of 750 mg) IV once on day 1

28-day cycle for 6 cycles

Subsequent treatment

MCLelderly, responders: Rituximab versus interferon alfa maintenance

Regimen variant #2, 40/25/375

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Rule et al. 2015 (CRUK-UCL-MCLIII)	2002-2010	Phase 3 (E-esc)	FC	Superior OS (primary endpoint)

Chemotherapy

Fludarabine (Fludara) by the following criteria:
- Standard patients: 40 mg/m² PO once per day on days 1 to 3
- Patients intolerant of the oral route: 25 mg/m² IV once per day on days 1 to 3
Cyclophosphamide (Cytoxan) by the following criteria:
- Standard patients: 250 mg/m² PO once per day on days 1 to 3
- Patients intolerant of the oral route: 250 mg/m² IV once per day on days 1 to 3

Targeted therapy

Rituximab (Rituxan) 375 mg/m² IV once on day 1

Supportive therapy

PJP prophylaxis was mandatory

28-day cycle for up to 8 cycles

References

MCLelderly: Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 Aug 9;367(6):520-31. link to original article contains dosing details in manuscript PubMed NCT00209209
1. Update: Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Geisler CH, Trneny M, Stilgenbauer S, Kaiser F, Doorduijn JK, Salles G, Szymczyk M, Tilly H, Kanz L, Schmidt C, Feugier P, Thieblemont C, Zijlstra JM, Ribrag V, Klapper W, Pott C, Unterhalt M, Dreyling MH. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. J Clin Oncol. 2020 Jan 20;38(3):248-256. Epub 2019 Dec 5. link to original article PubMed
CRUK-UCL-MCLIII: Rule S, Smith P, Johnson PW, Bolam S, Follows G, Gambell J, Hillmen P, Jack A, Johnson S, Kirkwood AA, Kruger A, Pocock C, Seymour JF, Toncheva M, Walewski J, Linch D. The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. Haematologica. 2016 Feb;101(2):235-40. Epub 2015 Nov 26. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00641095

MCP

MCP: Mitoxantrone, Chlorambucil, Prednisone

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Nickenig et al. 2006 (GLSG '96)	1996-1998	Phase 3 (E-switch-ic)	CHOP	Might have inferior ORR

Note: the chlorambucil dose is written in the reference as "3 x 3 mg/m²"; total dose per day is 9 mg/m².

Chemotherapy

Mitoxantrone (Novantrone) 8 mg/m² IV once per day on days 1 & 2
Chlorambucil (Leukeran) 3 mg/m² PO three times per day on days 1 to 5

Glucocorticoid therapy

Prednisone (Sterapred) 25 mg/m² PO once per day on days 1 to 5

28-day cycle for 6 to 8 cycles

References

GLSG '96: Nickenig C, Dreyling M, Hoster E, Pfreundschuh M, Trumper L, Reiser M, Wandt H, Lengfelder E, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer. 2006 Sep 1;107(5):1014-22. link to original article contains dosing details in manuscript PubMed

VAD+C

VAD+C: Vincristine, Adriamycin (Doxorubicin), Dexamethasone, Chlorambucil

Regimen

Study	Evidence
Gressin et al. 2010 (GOELAMS LM1996)	Phase 2

Chemotherapy

Vincristine (Oncovin) 0.4 mg/m²/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 1.6 mg/m²)
Doxorubicin (Adriamycin) 9 mg/m²/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 36 mg/m²)
Chlorambucil (Leukeran) 12 mg PO once per day on days 20 to 29

Glucocorticoid therapy

Dexamethasone (Decadron) 20 mg IV or PO twice per day on days 1 to 4

35-day cycle for 4 to 8 cycles

Subsequent treatment

GOELAMS LM1996, transplant-eligible patients with more than partial response after 4 cycles: High-dose melphalan & TBI, then autologous HSCT consolidation, 4 weeks after the 6th cycle

References

GOELAMS LM1996: Gressin R, Caulet-Maugendre S, Deconinck E, Tournilhac O, Gyan E, Moles MP, El Yamani A, Cornillon J, Rossi JF, Le Gouill S, Lepeu G, Damaj G, Celigny PS, Maisonneuve H, Corront B, Vilque JP, Casassus P, Lamy T, Colonna M, Colombat P; GOELAMS. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma: combined results of two prospective phase II trials from the French GOELAMS Group. Haematologica. 2010 Aug;95(8):1350-7. Epub 2010 Mar 10. link to original article contains dosing details in manuscript link to PMC article PubMed

Maintenance after first-line therapy

Interferon alfa monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Dreyling et al. 2004	1996-2004	Phase 3 (C)	Cy/TBI, then auto HSCT	Seems to have inferior PFS
Kluin-Nelemans et al. 2012 (MCLelderly)	2004-2010	Phase 3 (C)	Rituximab	Inferior combined OS¹

¹Inferiority was only demonstrated in the group of patients who got R-CHOP first; overall, there was no statistically significant survival difference between the two maintenance groups.
Note: Neither of these trials specified the type of interferon alfa used.

Preceding treatment

R-CHOP induction x 8 versus R-FC induction x 6

Immunotherapy

Interferon alfa

Continued indefinitely

References

Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005 Apr 1;105(7):2677-84. Epub 2004 Dec 9. link to original article PubMed
MCLelderly: Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 Aug 9;367(6):520-31. link to original article PubMed NCT00209209
1. Update: Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Geisler CH, Trneny M, Stilgenbauer S, Kaiser F, Doorduijn JK, Salles G, Szymczyk M, Tilly H, Kanz L, Schmidt C, Feugier P, Thieblemont C, Zijlstra JM, Ribrag V, Klapper W, Pott C, Unterhalt M, Dreyling MH. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. J Clin Oncol. 2020 Jan 20;38(3):248-256. Epub 2019 Dec 5. link to original article PubMed

Relapsed or refractory

CHOP (Prednisolone)

CHOP: Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Prednisolone

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Furtado et al. 2014 (NCRN-Ply-26s)	2007-2011	Randomized Phase 2 (C)	BCHOP	Inferior OS

Note: this regimen uses prednisolone.

Chemotherapy

Cyclophosphamide (Cytoxan) 750 mg/m² IV once on day 1
Doxorubicin (Adriamycin) 50 mg/m² IV once on day 1
Vincristine (Oncovin) 1.4 mg/m² (maximum dose of 2 mg) IV once on day 1

Glucocorticoid therapy

Prednisolone (Millipred) 100 mg PO once per day on days 1 to 5

21-day cycle for 6 to 8 cycles

References

NCRN-Ply-26s: Furtado M, Johnson R, Kruger A, Turner D, Rule S. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. Br J Haematol. 2015 Jan;168(1):55-62. Epub 2014 Aug 22. link to original article contains dosing details in manuscript PubMed NCT00513955

FCM

FCM: Fludarabine, Cyclophosphamide, Mitoxantrone

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Forstpointner et al. 2004	1998-2001	Phase 3 (C)	R-FCM	Inferior OS

Chemotherapy

Fludarabine (Fludara) 25 mg/m² IV over 30 minutes once per day on days 1 to 3
Cyclophosphamide (Cytoxan) 200 mg/m² IV over 4 hours on days 1 to 3
Mitoxantrone (Novantrone) 8 mg/m² IV over 30 minutes once on day 1

28-day cycle for 4 cycles

Subsequent treatment

Forstpointner et al. 2004, PR/CR: Rituximab maintenance versus no further treatment

References

Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, Böck HP, Wandt H, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004 Nov 15;104(10):3064-71. Epub 2004 Jul 29. link to original article contains dosing details in manuscript PubMed content property of HemOnc.org
1. Update: Forstpointner R, Unterhalt M, Dreyling M, Böck HP, Repp R, Wandt H, Pott C, Seymour JF, Metzner B, Hänel A, Lehmann T, Hartmann F, Einsele H, Hiddemann W; German Low Grade Lymphoma Study Group. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006 Dec 15;108(13):4003-8. Epub 2006 Aug 31. link to original article contains dosing details in manuscript PubMed

Fludarabine & Rituximab (FR)

FR: Fludarabine & Rituximab

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Rummel et al. 2015 (StiL NHL 2-2003)	2003-2010	Phase 3 (C)	BR	Seems to have inferior OS

Chemotherapy

Fludarabine (Fludara) 25 mg/m² (route not specified) once per day on days 1 to 3

Targeted therapy

Rituximab (Rituxan) 375 mg/m² IV once on day 1

28-day cycle for up to 6 cycles

References

StiL NHL 2-2003: Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck HP, Weidmann E, von Gruenhagen U, Mueller L, Sandherr M, Hahn L, Vereshchagina J, Kauff F, Blau W, Hinke A, Barth J; StiL. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016 Jan;17(1):57-66. Epub 2015 Dec 5. link to original article contains dosing details in abstract PubMed NCT01456351

@@ Line 3: / Line 3: @@
 [[#top|Back to Top]]
 </div>
-The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Mantle_cell_lymphoma|main MCL page]] for current regimens.
+The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the [[Mantle_cell_lymphoma|main MCL page]] for current regimens.
 {| class="wikitable" style="float:right; margin-right: 5px;"
 |-
@@ Line 13: / Line 13: @@
 ==CHOP {{#subobject:d6600|Regimen=1}}==
 CHOP: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone
-<div class="toccolours" style="background-color:#eeeeee">
+<div class="toccolours" style="background-color:#ee6b6e">
 ===Regimen {{#subobject:cc7182|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 45: / Line 45: @@
 </div></div>
 ===References===
-# Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M, Hiddemann W; German Low Grade Lymphoma Study Group. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005 Mar 20;23(9):1984-92. Epub 2005 Jan 24. [https://doi.org/10.1200/jco.2005.08.133 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15668467 PubMed]
+# Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M, Hiddemann W; German Low Grade Lymphoma Study Group. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005 Mar 20;23(9):1984-92. Epub 2005 Jan 24. [https://doi.org/10.1200/jco.2005.08.133 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15668467/ PubMed]
-# '''GLSG '96:''' Nickenig C, Dreyling M, Hoster E, Pfreundschuh M, Trumper L, Reiser M, Wandt H, Lengfelder E, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer. 2006 Sep 1;107(5):1014-22. [https://doi.org/10.1002/cncr.22093 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16878325 PubMed]
+# '''GLSG '96:''' Nickenig C, Dreyling M, Hoster E, Pfreundschuh M, Trumper L, Reiser M, Wandt H, Lengfelder E, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer. 2006 Sep 1;107(5):1014-22. [https://doi.org/10.1002/cncr.22093 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16878325/ PubMed]
-==FC {{#subobject:c122ba|Regimen=1}}==
+==Cyclophosphamide & Fludarabine (FC) {{#subobject:c122ba|Regimen=1}}==
 FC: '''<u>F</u>'''ludarabine, '''<u>C</u>'''yclophosphamide
-<div class="toccolours" style="background-color:#eeeeee">
+<div class="toccolours" style="background-color:#ee6b6e">
 ===Regimen {{#subobject:0d3d4b|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 74: / Line 74: @@
 **Patients intolerant of the oral route: 250 mg/m<sup>2</sup> IV once per day on days 1 to 3
 ====Supportive therapy====
-*PJP prophylaxis was mandatory
+*[[:Category:PCP_prophylaxis|PJP prophylaxis]] was mandatory
 '''28-day cycle for up to 8 cycles'''
 </div></div>
 ===References===
-# '''CRUK-UCL-MCLIII:''' Rule S, Smith P, Johnson PW, Bolam S, Follows G, Gambell J, Hillmen P, Jack A, Johnson S, Kirkwood AA, Kruger A, Pocock C, Seymour JF, Toncheva M, Walewski J, Linch D. The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. Haematologica. 2016 Feb;101(2):235-40. Epub 2015 Nov 26. [http://www.haematologica.org/content/101/2/235.long link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938327/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26611473 PubMed] NCT00641095
+# '''CRUK-UCL-MCLIII:''' Rule S, Smith P, Johnson PW, Bolam S, Follows G, Gambell J, Hillmen P, Jack A, Johnson S, Kirkwood AA, Kruger A, Pocock C, Seymour JF, Toncheva M, Walewski J, Linch D. The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. Haematologica. 2016 Feb;101(2):235-40. Epub 2015 Nov 26. [http://www.haematologica.org/content/101/2/235.long link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938327/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26611473/ PubMed] [https://clinicaltrials.gov/study/NCT00641095 NCT00641095]
 ==FCR {{#subobject:957676|Regimen=1}}==
 FCR: '''<u>F</u>'''ludarabine, '''<u>C</u>'''yclophosphamide, '''<u>R</u>'''ituximab
 <br> R-FC: '''<u>R</u>'''ituximab, '''<u>F</u>'''ludarabine, '''<u>C</u>'''yclophosphamide
-<div class="toccolours" style="background-color:#eeeeee">
+<div class="toccolours" style="background-color:#ee6b6e">
 ===Regimen variant #1, 30/250/375 {{#subobject:839caa|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 95: / Line 95: @@
 |style="background-color:#1a9851"|Phase 3 (E-switch-ic)
 |[[Mantle_cell_lymphoma#R-CHOP|R-CHOP]]
-|style="background-color:#d73027"|Inferior OS
+|style="background-color:#d73027"|Inferior OS (secondary endpoint)
 |-
 |}
@@ Line 110: / Line 110: @@
 *MCLelderly, responders: [[Mantle_cell_lymphoma#Rituximab_monotherapy|Rituximab]] versus [[Mantle_cell_lymphoma#Interferon_alfa_monotherapy|interferon alfa]] maintenance
 </div></div><br>
-<div class="toccolours" style="background-color:#eeeeee">
+<div class="toccolours" style="background-color:#ee6b6e">
 ===Regimen variant #2, 40/25/375 {{#subobject:9ecbf7|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 122: / Line 122: @@
 |2002-2010
 |style="background-color:#1a9851"|Phase 3 (E-esc)
-|[[#FC|FC]]
+|[[#Cyclophosphamide_.26_Fludarabine_.28FC.29|FC]]
-|style="background-color:#1a9850"|Superior OS
+|style="background-color:#1a9850"|Superior OS (primary endpoint)
 |-
 |}
@@ Line 141: / Line 141: @@
 </div></div>
 ===References===
-# '''MCLelderly:''' Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 Aug 9;367(6):520-31. [https://doi.org/10.1056/NEJMoa1200920 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22873532/ PubMed] NCT00209209
+# '''MCLelderly:''' Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 Aug 9;367(6):520-31. [https://doi.org/10.1056/NEJMoa1200920 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22873532/ PubMed] [https://clinicaltrials.gov/study/NCT00209209 NCT00209209]
-## '''Update:''' Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Geisler CH, Trneny M, Stilgenbauer S, Kaiser F, Doorduijn JK, Salles G, Szymczyk M, Tilly H, Kanz L, Schmidt C, Feugier P, Thieblemont C, Zijlstra JM, Ribrag V, Klapper W, Pott C, Unterhalt M, Dreyling MH. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. J Clin Oncol. 2020 Jan 20;38(3):248-256. Epub 2019 Dec 5. [https://doi.org/10.1200/jco.19.01294 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31804876 PubMed]
+## '''Update:''' Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Geisler CH, Trneny M, Stilgenbauer S, Kaiser F, Doorduijn JK, Salles G, Szymczyk M, Tilly H, Kanz L, Schmidt C, Feugier P, Thieblemont C, Zijlstra JM, Ribrag V, Klapper W, Pott C, Unterhalt M, Dreyling MH. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. J Clin Oncol. 2020 Jan 20;38(3):248-256. Epub 2019 Dec 5. [https://doi.org/10.1200/jco.19.01294 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31804876/ PubMed]
-# '''CRUK-UCL-MCLIII:''' Rule S, Smith P, Johnson PW, Bolam S, Follows G, Gambell J, Hillmen P, Jack A, Johnson S, Kirkwood AA, Kruger A, Pocock C, Seymour JF, Toncheva M, Walewski J, Linch D. The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. Haematologica. 2016 Feb;101(2):235-40. Epub 2015 Nov 26. [http://www.haematologica.org/content/101/2/235.long link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938327/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26611473 PubMed] NCT00641095
+# '''CRUK-UCL-MCLIII:''' Rule S, Smith P, Johnson PW, Bolam S, Follows G, Gambell J, Hillmen P, Jack A, Johnson S, Kirkwood AA, Kruger A, Pocock C, Seymour JF, Toncheva M, Walewski J, Linch D. The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. Haematologica. 2016 Feb;101(2):235-40. Epub 2015 Nov 26. [http://www.haematologica.org/content/101/2/235.long link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938327/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26611473/ PubMed] [https://clinicaltrials.gov/study/NCT00641095 NCT00641095]
 ==MCP {{#subobject:a84c0e|Regimen=1}}==
 MCP: '''<u>M</u>'''itoxantrone, '''<u>C</u>'''hlorambucil, '''<u>P</u>'''rednisone
-<div class="toccolours" style="background-color:#eeeeee">
+<div class="toccolours" style="background-color:#ee6b6e">
 ===Regimen {{#subobject:56b74a|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 172: / Line 172: @@
 </div></div>
 ===References===
-# '''GLSG '96:''' Nickenig C, Dreyling M, Hoster E, Pfreundschuh M, Trumper L, Reiser M, Wandt H, Lengfelder E, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer. 2006 Sep 1;107(5):1014-22. [https://doi.org/10.1002/cncr.22093 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16878325 PubMed]
+# '''GLSG '96:''' Nickenig C, Dreyling M, Hoster E, Pfreundschuh M, Trumper L, Reiser M, Wandt H, Lengfelder E, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer. 2006 Sep 1;107(5):1014-22. [https://doi.org/10.1002/cncr.22093 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16878325/ PubMed]
 ==VAD+C {{#subobject:69bd40|Regimen=1}}==
 VAD+C: '''<u>V</u>'''incristine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>D</u>'''examethasone, '''<u>C</u>'''hlorambucil
-<div class="toccolours" style="background-color:#eeeeee">
+<div class="toccolours" style="background-color:#ee6b6e">
 ===Regimen {{#subobject:cfee50|Variant=1}}===
 {| class="wikitable" style="width: 40%; text-align:center;"
@@ Line 196: / Line 196: @@
 <div class="toccolours" style="background-color:#cbd5e7">
 ====Subsequent treatment====
-*GOELAMS LM1996, transplant-eligible patients with more than partial response after 4 cycles: [[Mantle_cell_lymphoma#Melphalan_.26_TBI.2C_then_auto_HSCT|High-dose melphalan & TBI, then autologous HSCT]] 4 weeks after the 6th cycle
+*GOELAMS LM1996, transplant-eligible patients with more than partial response after 4 cycles: [[Mantle_cell_lymphoma#Melphalan_.26_TBI.2C_then_auto_HSCT|High-dose melphalan & TBI, then autologous HSCT]] consolidation, 4 weeks after the 6th cycle
 </div></div>
 ===References===
-# '''GOELAMS LM1996:''' Gressin R, Caulet-Maugendre S, Deconinck E, Tournilhac O, Gyan E, Moles MP, El Yamani A, Cornillon J, Rossi JF, Le Gouill S, Lepeu G, Damaj G, Celigny PS, Maisonneuve H, Corront B, Vilque JP, Casassus P, Lamy T, Colonna M, Colombat P; GOELAMS. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma: combined results of two prospective phase II trials from the French GOELAMS Group. Haematologica. 2010 Aug;95(8):1350-7. Epub 2010 Mar 10. [http://www.haematologica.org/content/95/8/1350.full link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913084/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20220059 PubMed]
+# '''GOELAMS LM1996:''' Gressin R, Caulet-Maugendre S, Deconinck E, Tournilhac O, Gyan E, Moles MP, El Yamani A, Cornillon J, Rossi JF, Le Gouill S, Lepeu G, Damaj G, Celigny PS, Maisonneuve H, Corront B, Vilque JP, Casassus P, Lamy T, Colonna M, Colombat P; GOELAMS. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma: combined results of two prospective phase II trials from the French GOELAMS Group. Haematologica. 2010 Aug;95(8):1350-7. Epub 2010 Mar 10. [http://www.haematologica.org/content/95/8/1350.full link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913084/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/20220059/ PubMed]
 =Maintenance after first-line therapy=
 ==Interferon alfa monotherapy {{#subobject:f7b23b|Regimen=1}}==
-<div class="toccolours" style="background-color:#eeeeee">
+<div class="toccolours" style="background-color:#ee6b6e">
 ===Regimen {{#subobject:e5b536|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 228: / Line 228: @@
 <div class="toccolours" style="background-color:#cbd5e8">
 ====Preceding treatment====
-*[[Mantle_cell_lymphoma#R-CHOP|R-CHOP]] x 8 versus [[#FCR|R-FC]] x 6
+*[[Mantle_cell_lymphoma#R-CHOP|R-CHOP]] induction x 8 versus [[#FCR|R-FC]] induction x 6
 </div>
 <div class="toccolours" style="background-color:#b3e2cd">
 ====Immunotherapy====
-*[[:Category:Interferon_alfa|Interferon alfa]]
+*[[:Category:Interferon_alfas|Interferon alfa]]
 '''Continued indefinitely'''
 </div></div>
 ===References===
 # Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005 Apr 1;105(7):2677-84. Epub 2004 Dec 9. [http://www.bloodjournal.org/content/105/7/2677.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/15591112/ PubMed]
-# '''MCLelderly:''' Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 Aug 9;367(6):520-31. [https://doi.org/10.1056/NEJMoa1200920 link to original article] [https://pubmed.ncbi.nlm.nih.gov/22873532/ PubMed] NCT00209209
+# '''MCLelderly:''' Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 Aug 9;367(6):520-31. [https://doi.org/10.1056/NEJMoa1200920 link to original article] [https://pubmed.ncbi.nlm.nih.gov/22873532/ PubMed] [https://clinicaltrials.gov/study/NCT00209209 NCT00209209]
-## '''Update:''' Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Geisler CH, Trneny M, Stilgenbauer S, Kaiser F, Doorduijn JK, Salles G, Szymczyk M, Tilly H, Kanz L, Schmidt C, Feugier P, Thieblemont C, Zijlstra JM, Ribrag V, Klapper W, Pott C, Unterhalt M, Dreyling MH. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. J Clin Oncol. 2020 Jan 20;38(3):248-256. Epub 2019 Dec 5. [https://doi.org/10.1200/jco.19.01294 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31804876 PubMed]
+## '''Update:''' Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Geisler CH, Trneny M, Stilgenbauer S, Kaiser F, Doorduijn JK, Salles G, Szymczyk M, Tilly H, Kanz L, Schmidt C, Feugier P, Thieblemont C, Zijlstra JM, Ribrag V, Klapper W, Pott C, Unterhalt M, Dreyling MH. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. J Clin Oncol. 2020 Jan 20;38(3):248-256. Epub 2019 Dec 5. [https://doi.org/10.1200/jco.19.01294 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31804876/ PubMed]
 =Relapsed or refractory=
 ==CHOP (Prednisolone) {{#subobject:a01b9f|Regimen=1}}==
 CHOP: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisolone
-<div class="toccolours" style="background-color:#eeeeee">
+<div class="toccolours" style="background-color:#ee6b6e">
 ===Regimen {{#subobject:ebce4e|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 270: / Line 271: @@
 ===References===
 <!-- Previously presented in part (in poster form) at the 17th Congress of the European Haematology Association, June 2012 and orally at the BSH annual scientific meeting 2013. -->
-# '''NCRN-Ply-26s:''' Furtado M, Johnson R, Kruger A, Turner D, Rule S. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. Br J Haematol. 2015 Jan;168(1):55-62. Epub 2014 Aug 22. [https://doi.org/10.1111/bjh.13101 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/25146720/ PubMed] NCT00513955
+# '''NCRN-Ply-26s:''' Furtado M, Johnson R, Kruger A, Turner D, Rule S. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. Br J Haematol. 2015 Jan;168(1):55-62. Epub 2014 Aug 22. [https://doi.org/10.1111/bjh.13101 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/25146720/ PubMed] [https://clinicaltrials.gov/study/NCT00513955 NCT00513955]
 ==FCM {{#subobject:ddc2e3|Regimen=1}}==
 FCM: '''<u>F</u>'''ludarabine, '''<u>C</u>'''yclophosphamide, '''<u>M</u>'''itoxantrone
-<div class="toccolours" style="background-color:#eeeeee">
+<div class="toccolours" style="background-color:#ee6b6e">
 ===Regimen {{#subobject:32ca30|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 302: / Line 303: @@
 ===References===
 # Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, Böck HP, Wandt H, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004 Nov 15;104(10):3064-71. Epub 2004 Jul 29. [http://www.bloodjournal.org/content/104/10/3064.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/15284112/ PubMed] content property of [http://hemonc.org HemOnc.org]
-## '''Update:''' Forstpointner R, Unterhalt M, Dreyling M, Böck HP, Repp R, Wandt H, Pott C, Seymour JF, Metzner B, Hänel A, Lehmann T, Hartmann F, Einsele H, Hiddemann W; German Low Grade Lymphoma Study Group. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006 Dec 15;108(13):4003-8. Epub 2006 Aug 31. [http://www.bloodjournal.org/content/108/13/4003.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16946304 PubMed]
+## '''Update:''' Forstpointner R, Unterhalt M, Dreyling M, Böck HP, Repp R, Wandt H, Pott C, Seymour JF, Metzner B, Hänel A, Lehmann T, Hartmann F, Einsele H, Hiddemann W; German Low Grade Lymphoma Study Group. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006 Dec 15;108(13):4003-8. Epub 2006 Aug 31. [http://www.bloodjournal.org/content/108/13/4003.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16946304/ PubMed]
 ==Fludarabine & Rituximab (FR) {{#subobject:d61742|Regimen=1}}==
 FR: '''<u>F</u>'''ludarabine & '''<u>R</u>'''ituximab
-<div class="toccolours" style="background-color:#eeeeee">
+<div class="toccolours" style="background-color:#ee6b6e">
 ===Regimen {{#subobject:2592a5|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 331: / Line 332: @@
 <!-- # '''Abstract:''' Mathias J. Rummel, MD, PhD, Ulrich Kaiser, MD, Christina Balser, Martina Beate Stauch, Wolfram Brugger, MD, PhD, Manfred Welslau, Norbert Niederle, Christoph Losem, Harald Ballo, Eckhart Weidmann, Ulrich von Gruenhagen, Lothar Mueller, Michael Sandherr, MD, Julia Vereschagina, Axel Hinke and Juergen Barth. Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas – Final Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany). ASH Annual Meeting 2010, Abstract 856 [https://ash.confex.com/ash/2010/webprogram/Paper26917.html link to abstract]
 ## '''Update:''' '''Abstract:''' Mathias J. Rummel, MD, Christina Balser, MD, Ulrich Kaiser, MD, Hans Peter Böck, Martina Beate Stauch, MD, Andrea Heider, PhD, Manfred Welslau, Christoph Losem, Eckhart Weidmann, Wolfgang Blau, MD, Alexander Burchardt, MD, Jürgen Barth, Frank Kauff, PhD, Axel Hinke, PhD and Wolfram Brugger, MD. Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab in Patients with Relapsed Follicular, Indolent, or Mantle Cell Lymphomas – 8-Year Follow-up Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany). ASH Annual Meeting 2014, Abstract 145 [https://ash.confex.com/ash/2014/webprogram/Paper69154.html link to abstract] -->
-# '''StiL NHL 2-2003:''' Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck HP, Weidmann E, von Gruenhagen U, Mueller L, Sandherr M, Hahn L, Vereshchagina J, Kauff F, Blau W, Hinke A, Barth J; StiL. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016 Jan;17(1):57-66. Epub 2015 Dec 5. [https://doi.org/10.1016/S1470-2045(15)00447-7 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/26655425 PubMed] NCT01456351
+# '''StiL NHL 2-2003:''' Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck HP, Weidmann E, von Gruenhagen U, Mueller L, Sandherr M, Hahn L, Vereshchagina J, Kauff F, Blau W, Hinke A, Barth J; StiL. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016 Jan;17(1):57-66. Epub 2015 Dec 5. [https://doi.org/10.1016/S1470-2045(15)00447-7 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/26655425/ PubMed] [https://clinicaltrials.gov/study/NCT01456351 NCT01456351]
 [[Category:Mantle cell lymphoma regimens]]
 [[Category:Disease-specific pages]]
-[[Category:Aggressive lymphomas]]
+[[Category:Aggressive non-Hodgkin lymphomas]]
-[[Category:Non-Hodgkin lymphomas]]
+[[Category:B-cell lymphomas]]
 [[Category:Historical regimens]]

Difference between revisions of "Mantle cell lymphoma - historical"

Revision as of 11:25, 13 May 2024

First-line therapy

CHOP

Regimen

Chemotherapy

Glucocorticoid therapy

References

Cyclophosphamide & Fludarabine (FC)

Regimen

Chemotherapy

Supportive therapy

References

FCR

Regimen variant #1, 30/250/375

Chemotherapy

Targeted therapy

Subsequent treatment

Regimen variant #2, 40/25/375

Chemotherapy

Targeted therapy

Supportive therapy

References

MCP

Regimen

Chemotherapy

Glucocorticoid therapy

References

VAD+C

Regimen

Chemotherapy

Glucocorticoid therapy

Subsequent treatment

References

Maintenance after first-line therapy

Interferon alfa monotherapy

Regimen

Preceding treatment

Immunotherapy

References

Relapsed or refractory

CHOP (Prednisolone)

Regimen

Chemotherapy

Glucocorticoid therapy

References

FCM

Regimen

Chemotherapy

Subsequent treatment

References

Fludarabine & Rituximab (FR)

Regimen

Chemotherapy

Targeted therapy

References

Navigation menu

Search